A Study of Pembrolizumab (MK-3475) in Combination With Belzutifan (MK-6482) and Lenvatinib (MK-7902), or Pembrolizumab/Quavonlimab (MK-1308A) in Combination With Lenvatinib, Versus Pembrolizumab and Lenvatinib, for Treatment of Advanced Clear Cell Renal Cell Carcinoma (MK-6482-012)

~12 mi. (Elizabeth Vale, Australia, +144 more cities)

Lyell McEwin Hospital ( Site 4004)

Clear Cell Renal Cell Carcinoma

belzutifan, +3 more drugs

immunotherapy, +1 more type

Study of Nivolumab Versus Placebo in Combination With Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy in Participants With High-risk, Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor 2-Negative (HER2-) Primary Breast Cancer

~12 mi. (Elizabeth Vale, Australia, +247 more cities)

Calvary Central Districts Hospital

ER Positive, +1 more biomarker

Breast Invasive Ductal Carcinoma

anthracycline, +4 more drugs

chemotherapy, +2 more types

Perioperative Enfortumab Vedotin (EV) Plus Pembrolizumab (MK-3475) Versus Neoadjuvant Chemotherapy for Cisplatin-eligible Muscle Invasive Bladder Cancer (MIBC) (MK-3475-B15/ KEYNOTE-B15 / EV-304)

~12 mi. (Elizabeth Vale, Australia, +93 more cities)

Lyell McEwin Hospital ( Site 1252)

Bladder Carcinoma, +1 more condition

cisplatin, +4 more drugs

chemotherapy, +3 more types

A Study of Belzutifan (MK-6482) in Combination With Lenvatinib Versus Cabozantinib for Treatment of Renal Cell Carcinoma (MK-6482-011)

~12 mi. (Elizabeth Vale, Australia, +93 more cities)

Lyell McEwin Hospital ( Site 4004)

Clear Cell Renal Cell Carcinoma

belzutifan, +1 more drug

targeted therapy

A Study of Ociperlimab With Tislelizumab Compared to Pembrolizumab in Participants With Untreated Lung Cancer

~12 mi. (Elizabeth Vale, Australia, +160 more cities)

Lyell McEwin Hospital

PD-L1 High Expression (TPS >= 50%)

Non-Squamous Non-Small Cell Lung Carcinoma, +1 more condition

ociperlimab, +1 more drug

immunotherapy

A Study of Nivolumab, Nivolumab Plus Ipilimumab, or Investigator's Choice Chemotherapy for the Treatment of Participants With Deficient Mismatch Repair (dMMR)/Microsatellite Instability High (MSI-H) Metastatic Colorectal Cancer (mCRC)

~12 mi. (Elizabeth Vale, Australia, +145 more cities)

Calvary Central Districts Hospital

Deficient DNA Mismatch Repair (dMMR), +5 more biomarkers

Colorectal Carcinoma

ipilimumab, +1 more drug

immunotherapy

Tislelizumab Plus BGB-A1217 Versus Tislelizumab Versus Durvalumab When Co-administered With Concurrent Chemoradiotherapy (cCRT) in Lung Cancer

~12 mi. (Elizabeth Vale, Australia, +7 more cities)

Lyell McEwin Hospital

Non-Small Cell Lung Carcinoma

chemotherapy, +3 more drugs

chemotherapy, +1 more type

An Investigational Immuno-therapy Study Of Nivolumab In Combination With Trametinib With Or Without Ipilimumab In Participants With Previously Treated Cancer of the Colon or Rectum That Has Spread

~12 mi. (Elizabeth Vale, Australia, +78 more cities)

Local Institution

Colorectal Adenocarcinoma

ipilimumab, +3 more drugs

immunotherapy, +1 more type

Study to Evaluate Monotherapy and Combination Immunotherapies in Participants With PD-L1 Positive Non-small Cell Lung Cancer

~12 mi. (Elizabeth Vale, Australia, +66 more cities)

Adelaide Cancer Centre

PD-L1 Expression (CPS >= 1), +5 more biomarkers

Non-Squamous Non-Small Cell Lung Carcinoma, +1 more condition

domvanalimab, +2 more drugs

immunotherapy

Tavo and Pembrolizumab in Patients With Stage III/IV Melanoma Progressing on Pembrolizumab or Nivolumab Treatment

~12 mi. (Elizabeth Vale, Australia, +36 more cities)

Cavalry Central Districts Hospital

Melanoma

pembrolizumab, +1 more drug

immunotherapy

Tavo and Pembrolizumab With or Without Chemotherapy in Patients With Inoperable Locally Advanced or Metastatic TNBC

~12 mi. (Elizabeth Vale, Australia, +10 more cities)

Calvary Central Districts Hospital

ER Negative, +2 more biomarkers

Breast Carcinoma

pembrolizumab, +1 more drug

immunotherapy

Study of Single Agent Belantamab Mafodotin Versus Pomalidomide Plus Low-dose Dexamethasone (Pom/Dex) in Participants With Relapsed/Refractory Multiple Myeloma (RRMM)

~27 mi. (Woodville, Australia, +141 more cities)

GSK Investigational Site

Multiple Myeloma

belantamab mafodotin

chemotherapy, +1 more type